Built on an ideal pharmacokinetic profile
"Lev comes especially close to fulfilling the desirable pharmacokinetics
characteristics for an AED"
(Perucca E, Epileptic Disord. 2003; 5 suppl2: S17-26)
Ideal pharmacokinetics
Adapted from Patsalos PN, Pharmacology & Therapeutics
2000; 85: 77-85
Levetiracetam: linear pharmacokinetics
Adapted from Patsalos PN, Pharmacology & Therapeutics
2000; 85: 77-85
No Known pharmacokinetic drug-drug interactions
^ increased plasma concentration.
v Decreased plasma concentration.
0 No change.
- Not determined.
a) Interactions were studied for the active metabolite, MHD.
b) <10% change in plasma concentration.
c) Seen at doses >1200-2400 mg/day.
d) About 10%.
e) Seen generally with BID dosing of phenytoin.
v Decreased plasma concentration.
0 No change.
- Not determined.
a) Interactions were studied for the active metabolite, MHD.
b) <10% change in plasma concentration.
c) Seen at doses >1200-2400 mg/day.
d) About 10%.
e) Seen generally with BID dosing of phenytoin.
